Overview

Immunohistochemical Study of Neurodegenerative Diseases

Status:
Active, not recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The subject uses cytof to analyze PBMC of sporadic AD and DLB, which is used to reveal the differences in immune characteristics of the two diseases at the single-cell level, build immune models for specific diseases, and define these two neurodegenerative diseases with high precision from the level of molecular immunity. To provide basis for further study of the immunohistochemical differences between the two diseases, and provide objective support for clinical diagnosis and differential diagnosis.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Treatments:
Donepezil